BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 30253203)

  • 41. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
    Tang SC; de Vries N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and
    Verheijen RB; Yaqub M; Sawicki E; van Tellingen O; Lammertsma AA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR; Hendrikse NH; Steeghs N
    J Nucl Med; 2018 Jun; 59(6):973-979. PubMed ID: 29175983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice.
    F Martins ML; Loos NHC; El Yattouti M; Offeringa L; Heydari P; Hillebrand MJX; Lebre MC; Beijnen JH; Schinkel AH
    Pharm Res; 2023 Aug; 40(8):1885-1899. PubMed ID: 37344602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.
    Loos NHC; Martins MLF; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Int J Pharm; 2024 Jan; 650():123708. PubMed ID: 38135258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs.
    Li W; Sparidans RW; Wang Y; Martins MLF; de Waart DR; van Tellingen O; Song JY; Lebre MC; van Hoppe S; Wagenaar E; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2024 Jun; 175():116644. PubMed ID: 38692057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
    Hill CR; Jamieson D; Thomas HD; Brown CD; Boddy AV; Veal GJ
    Biochem Pharmacol; 2013 Jan; 85(1):29-37. PubMed ID: 23063411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
    van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
    Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice.
    Song YK; Kim MJ; Kim MS; Lee JH; Chung SJ; Song JS; Chae YJ; Lee KR
    Eur J Pharm Sci; 2022 Jun; 173():106177. PubMed ID: 35341895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
    Lin F; de Gooijer MC; Roig EM; Buil LC; Christner SM; Beumer JH; Würdinger T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2014 May; 20(10):2703-13. PubMed ID: 24647572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
    Zhang P; de Gooijer MC; Buil LC; Beijnen JH; Li G; van Tellingen O
    Int J Cancer; 2015 Oct; 137(8):2007-18. PubMed ID: 25868794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
    Lagas JS; van Waterschoot RA; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Cancer Ther; 2010 Feb; 9(2):319-26. PubMed ID: 20103600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.
    F Martins ML; Heydari P; Li W; Martínez-Chávez A; Venekamp N; Lebre MC; Lucas L; Beijnen JH; Schinkel AH
    Front Pharmacol; 2022; 13():855000. PubMed ID: 35308219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
    Marchetti S; Pluim D; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Invest New Drugs; 2014 Dec; 32(6):1083-95. PubMed ID: 25078948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
    Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
    Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
    Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
    Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.